Source:http://linkedlifedata.com/resource/pubmed/id/20009886
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2009-12-16
|
pubmed:abstractText |
We studied preoperative CA-125 levels of 123 patients with borderline ovarian tumors (BOTs) and performed an analysis with data of earlier published studies. CA-125 levels were compared according to histology and stage of disease. Preoperative serum CA-125 levels were significantly higher for patients with advanced stage (median, 181 U/mL; range, 413 U/mL) compared with patients with stage I (median, 28 U/mL; range, 1123 U/mL) BOTs and for patients with serous (median, 59 U/mL; range, 1119 U/mL) compared with patients with mucinous (median, 25 U/mL; range, 371 U/mL) BOTs (both P < 0.001, Mann-Whitney U test). A pooled analysis of 3 studies and the present study showed positive rates of CA-125 (value >35 U/mL) in 171 (53%) of 325 patients with BOTs. Positive rates were more often found in patients with serous (67%) compared with patients with mucinous BOTs (39%) and in patients with advanced stage (83%) compared with patients with stage I BOTs (47%) (both P < 0.001, Pearson chi(2) test). This main effect was also found for each individual study of the pooled analysis. From a clinical perspective, we believe, on base of the results of this study and the literature, that preoperative discrimination using CA-125 level is especially difficult between patients with stage I ovarian cancer and the group of patients with serous and/or advanced-stage BOTs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1525-1438
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1335-8
|
pubmed:meshHeading |
pubmed-meshheading:20009886-Adenocarcinoma, Mucinous,
pubmed-meshheading:20009886-Adult,
pubmed-meshheading:20009886-Aged,
pubmed-meshheading:20009886-Aged, 80 and over,
pubmed-meshheading:20009886-CA-125 Antigen,
pubmed-meshheading:20009886-Cystadenocarcinoma, Serous,
pubmed-meshheading:20009886-Female,
pubmed-meshheading:20009886-Humans,
pubmed-meshheading:20009886-Middle Aged,
pubmed-meshheading:20009886-Neoplasm Staging,
pubmed-meshheading:20009886-Ovarian Neoplasms,
pubmed-meshheading:20009886-Preoperative Care,
pubmed-meshheading:20009886-Prognosis,
pubmed-meshheading:20009886-Retrospective Studies,
pubmed-meshheading:20009886-Risk Factors,
pubmed-meshheading:20009886-Young Adult
|
pubmed:year |
2009
|
pubmed:articleTitle |
Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. E.Kolwijck@obgyn.umcn.nl
|
pubmed:publicationType |
Journal Article
|